Antineoplastic Agents: Cytotoxic Agents: Antitumor Antibiotics
IZAVE1 “Zavedos injection” 5 mg/vial
適應症：成人的急性非淋巴性白血病(ANLL)、成人與孩童的急性淋巴性白血病(ALL)。
Usual dose:
Leukemia, acute myeloid (induction): IV 12 mg/m2 daily for 3 days in combination with cytarabine; cytarabine can be dosed as 100 mg/m2 qd by continuous infusion for 7 days or as 25 mg/m2 IV bolus followed by 200 mg/m2 every day by continuous infusion for 5 days. PO 30 mg/m2 for 3 days.
Leukemia, acute myeloid (consolidation): 10-12 mg/m2 IV daily for 2 days. PO 30 mg/m2 for 3 days.
Lymphoma, non-Hodgkin’s: 10 mg/m2 IV on day 1 in combination with other chemotherapy agents has been used.
Dose adjustment:
Hepatic Insufficiency: should not be administered if the bilirubin level exceeds 5 mg/dL.
Adverse effect:
Common: diarrhea, N/V, alopecia, rash, urticaria, headache.
Serious: myelosuppression, mucositis, arrhythmias, chest pain, CHF, myocardial infarction, hepatotoxicity, renal toxicity, infection.